Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety
August 31 2020 - 9:00AM
MannKind Corporation (NASDAQ: MNKD) today
announced that Kevin Kaiserman, MD, has joined the company as Vice
President, Medical Affairs and Safety and will assume full
responsibility for leading MannKind’s medical affairs, field
medical activities, safety, and pediatrics initiatives. Dr.
Kaiserman will report directly to Michael Castagna, Chief Executive
Officer and will be based in MannKind’s Westlake Village,
California headquarters.
“As a board-certified pediatric endocrinologist,
Kevin brings significant expertise in the field of type 1 diabetes,
and is an integral addition to MannKind as we expand our medical
affairs capabilities and advance our pediatrics program,” said
Michael Castagna, Chief Executive Officer of MannKind. “His deep
expertise in continuous glucose monitoring and insulin delivery,
coupled with his lengthy experience in educating the endocrinology
community, will be instrumental in moving our medical initiatives
forward and supporting the effort to expand our Afrezza user
base.”
Dr. Kaiserman’s career includes over 25 years of
experience in pediatric endocrinology. For the past 14 years, he
has provided clinical management and research for type 1 diabetes
patients at his private practice, SoCal Diabetes. Prior to entering
private practice, Dr. Kaiserman was a Clinical Associate Professor
of Pediatrics and Medical Director of the Clinical Diabetes Program
at Children’s Hospital Los Angeles and the University of Southern
California, Keck School of Medicine. Dr. Kaiserman earned his
medical degree from Eastern Virginia Medical School in Norfolk. He
completed his internship and residency in the Department of
Pediatrics and his fellowship in the Division of Pediatric
Endocrinology at the University of California, Los Angeles.
A renowned speaker and thought leader in the
field of diabetes, Dr. Kaiserman has participated in numerous
publications and research studies. He is board certified in
pediatric endocrinology and is a member of the American Diabetes
Association, the Pediatric Endocrine Society, and the Board of
Directors of the Los Angeles Chapter of the Juvenile Diabetes
Research Foundation. Dr. Kaiserman is the Medical Director of Camp
Conrad-Chinnock, a camping program for children and adolescents
with diabetes, and serves on the Board of Directors for the
international Diabetes Education and Camping Association.
“I’m thrilled to join MannKind during this
exciting time of expansion,” said Dr. Kaiserman. “Afrezza is a
novel treatment option that provides mealtime control and
flexibility for adults living with type 1 and type 2 diabetes. I
look forward to working with my colleagues across the country to
study this therapy in pediatrics and hope to bring the benefits of
Afrezza to children and adolescents living with diabetes. I’ve seen
the rapid rate of innovation around diabetes management over the
past decades and am honored to lead the medical team at a company
that is changing the way people living with diabetes take control
of their health.”
About MannKind
CorporationMannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company’s first
FDA-approved product and the only inhaled ultra rapid-acting
mealtime insulin in the United States, where it is available by
prescription from pharmacies nationwide. MannKind is
headquartered in Westlake Village, California, and has a
state-of-the art manufacturing facility in Danbury, Connecticut.
The Company also employs field sales and medical representatives
across the U.S. For further information, visit
www.mannkindcorp.com.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. Words such as "believes," "anticipates,"
"plans," "expects," "intends," "will," "goal," "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based
upon MannKind's current expectations. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties detailed in MannKind's filings with
the SEC. For a discussion of these and other factors, please
refer to MannKind’s annual report on Form 10-K for the year
ended December 31, 2019 as well as MannKind’s other filings
with the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement,
and MannKind undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date of this press release.
Company
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024